Kingdon Capital Management’s Eledon Pharmaceuticals ELDN Stock Holding History

Kingdon Capital Management’s Portfolio ELDN Stock Details ELDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$3.2M	Hold	1,039,275	–	–	0.35%	59
2025 Q4	$1.57M	Buy	+1,039,275	New	+$2.47M	0.19%	66
2016 Q1	–	Sell	-543	Closed	-$767K	–	119
2015 Q4	$767K	Sell	543 -3,521	-87%	-$6.13M	0.04%	112
2015 Q3	$6.81M	Sell	4,064 -510	-11%	-$1.05M	0.33%	72
2015 Q2	$9.86M	Buy	4,574 +389	+9%	+$753K	0.39%	78
2015 Q1	$7.66M	Buy	4,185 +679	+19%	+$1.5M	0.33%	85
2014 Q4	$8.37M	Buy	3,506 +2,241	+177%	+$5.32M	0.36%	79
2014 Q3	$3.1M	Buy	+1,265	New	+$3.6M	0.14%	132

Other funds holding ELDN

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DCM

Defilade Capital Management Emeryville, California $712M AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return

Zimmer Partners New York $4.15B AUM 14.2% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

CCM

Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

Kingdon Capital Management's ELDN Position: Q1 2026 in Review

Kingdon Capital Management held its Eledon Pharmaceuticals (ELDN) position steady in Q1 2026 at 1,039,275 shares worth $3.2M. The position accounts for 0.35% of the portfolio, ranked #59.

Kingdon Capital Management first reported a position in ELDN in Q3 2014 and has held it in 8 quarters since. The position peaked at $9.86M in Q2 2015. 121 funds tracked by Wall St. Rank hold ELDN as of Q1 2026.

Kingdon Capital Management held 1,039,275 shares of Eledon Pharmaceuticals worth $3.2M as of Q1 2026.
Kingdon Capital Management left its Eledon Pharmaceuticals share count unchanged in Q1 2026.
Eledon Pharmaceuticals made up 0.35% of Kingdon Capital Management's portfolio in Q1 2026, its #59 holding.
Kingdon Capital Management first reported a position in Eledon Pharmaceuticals in Q3 2014 and has held it in 8 quarters since.
Kingdon Capital Management's Eledon Pharmaceuticals position peaked at $9.86M in Q2 2015.
121 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q1 2026.

Based on Kingdon Capital Management's 13F filing for Q1 2026, filed 15 May 2026.